Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Treatment-Refractory Solid Tumors 1

Interventions

Injections 9Interviews as Topic 5Carboplatin 5Cisplatin 4toripalimab 3fludarabine 3Pemetrexed 3Iodine-125 3Immune Checkpoint Inhibitors 3Fluorodeoxyglucose F18 3tislelizumab 2envafolimab 2Specimen Handling 2Paclitaxel 2Oxaliplatin 2Drug Therapy 2Cyclophosphamide 2Cryosurgery 2Capecitabine 2Blood Specimen Collection 2trastuzumab deruxtecan 1spartalizumab 1somatostatin receptor 2 1sintilimab 1regorafenib 1pembrolizumab 1osimertinib 1olaparib 1nabiximols 1malic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Hydroxyurea × Other solid neoplasm × Clear all
NCT07170592 2026-04-07

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Bionoxx Inc.

Phase 1 Not yet recruiting
24 enrolled
Other solid neoplasm

Treatment-Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡